European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

NCT00412698 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

645

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision has been taken in light of recent demands by certain national health authorities

Conditions

Obesity
Dyslipidemias

Interventions

DRUG: rimonabant
DRUG: Placebo

Sponsor

Sanofi